Carpal Tunnel Syndrome Clinical Trial
— ACTSOfficial title:
The Use of N-acetylcysteine Supplementation in Addition to Night Splinting for Treatment of Mild to Moderate Carpal Tunnel Syndrome: A Randomized, Double-blind, Placebo-controlled Trial
Carpal tunnel syndrome (CTS) is the most common nerve compression syndrome worldwide, causing significant chronic pain, functional impairment, and lowered quality of life for individuals of various backgrounds. CTS is caused by chronic compression of the median nerve in the carpal tunnel of the wrist, causing numbness and pain in the palm, thumb, index, and middle fingers and eventual weakness of the hand. Many different treatments for CTS have been proposed and studied, including but not limited to non-operative treatments such as wrist splinting, steroid injections, and lifestyle modifications as well as operative treatments, such as surgical carpal tunnel release (CTR). To date, very few oral medications have been shown to be effective as conservative treatments for CTS. In this study the investigators will examine whether there is any benefit to using oral N-acetylcysteine (NAC) as an adjunctive treatment for mild to moderate CTS in addition to a standard 8-week trial of night splinting. NAC has been used in humans for various purposes, is extremely safe and has very few side effects, and has been shown to have anti-inflammation properties which may help treat CTS. The investigators will study this by performing a randomized controlled trial, comparing patients receiving oral NAC and standard night splinting to patients receiving an identical placebo and standard night splinting. Both patient groups will be assessed using a questionnaire to assess for severity of their CTS symptoms both before and after the 8-week treatment. The primary objective will be to determine whether supplementation with oral NAC in addition to night splinting has any significant impact on patient-reported symptoms and functional impairment when compared to night splinting alone. The investigators will also measure secondary outcomes including whether patients decide to have surgery for their CTS after treatment and/or continued use of other treatments. This study has the potential to have a significant positive impact on patients by identifying a safe, inexpensive, accessible, and well tolerated conservative treatment for mild to moderate carpal tunnel syndrome, and potentially preventing the need for additional, more invasive treatments such as surgery.
Status | Recruiting |
Enrollment | 240 |
Est. completion date | May 1, 2023 |
Est. primary completion date | December 1, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. The patient has a confirmed diagnosis of mild to moderate idiopathic unilateral or bilateral CTS as determined by both clinical exam findings and electrodiagnostic nerve conduction studies (median nerve distal motor latency = 4.3 milliseconds and/or median nerve sensory distal latency = 3.5 milliseconds at the wrist) performed within the preceding year prior to enrollment 2. Symptoms of CTS must have been present for = 6 weeks 3. The patient must be = 18 years of age. Exclusion Criteria: 1. Any previous carpal tunnel release procedure on the ipsilateral limb 2. Any previous trial of night splinting or corticosteroid injection in the last 6 months on the ipsilateral limb 3. Severe CTS/signs of median nerve denervation with axonal loss determined by constant wrist or hand pain, constant parasthesias in the median nerve distribution, or thenar muscle atrophy in the ipsilateral limb 4. Any known or suspected allergy to NAC 5. Any current medications which preclude use of NAC including antibiotics or nitroglycerin 6. Breastfeeding patients or patients with nephrolithiasis 7. Any history of proximal ipsilateral neck or proximal limb injury 8. Secondary CTS related to pregnancy 9. Unable for financial reasons to obtain a night splint (i.e. lack of insurance coverage or lack of financial means). |
Country | Name | City | State |
---|---|---|---|
Canada | Queen Elizabeth II Health Sciences Center, Halifax Infirmary Site | Halifax | Nova Scotia |
Lead Sponsor | Collaborator |
---|---|
David Tang |
Canada,
Atroshi I, Gummesson C, Johnsson R, Ornstein E, Ranstam J, Rosén I. Prevalence of carpal tunnel syndrome in a general population. JAMA. 1999 Jul 14;282(2):153-8. — View Citation
Chan KM, Gordon T, Zochodne DW, Power HA. Improving peripheral nerve regeneration: from molecular mechanisms to potential therapeutic targets. Exp Neurol. 2014 Nov;261:826-35. doi: 10.1016/j.expneurol.2014.09.006. Epub 2014 Sep 16. Review. — View Citation
Chesterton LS, Blagojevic-Bucknall M, Burton C, Dziedzic KS, Davenport G, Jowett SM, Myers HL, Oppong R, Rathod-Mistry T, van der Windt DA, Hay EM, Roddy E. The clinical and cost-effectiveness of corticosteroid injection versus night splints for carpal tunnel syndrome (INSTINCTS trial): an open-label, parallel group, randomised controlled trial. Lancet. 2018 Oct 20;392(10156):1423-1433. doi: 10.1016/S0140-6736(18)31572-1. — View Citation
Huisstede BM, Fridén J, Coert JH, Hoogvliet P; European HANDGUIDE Group. Carpal tunnel syndrome: hand surgeons, hand therapists, and physical medicine and rehabilitation physicians agree on a multidisciplinary treatment guideline-results from the European HANDGUIDE Study. Arch Phys Med Rehabil. 2014 Dec;95(12):2253-63. doi: 10.1016/j.apmr.2014.06.022. Epub 2014 Aug 12. — View Citation
Kim JK, Koh YD, Kim JS, Hann HJ, Kim MJ. Oxidative stress in subsynovial connective tissue of idiopathic carpal tunnel syndrome. J Orthop Res. 2010 Nov;28(11):1463-8. doi: 10.1002/jor.21163. — View Citation
Levine DW, Simmons BP, Koris MJ, Daltroy LH, Hohl GG, Fossel AH, Katz JN. A self-administered questionnaire for the assessment of severity of symptoms and functional status in carpal tunnel syndrome. J Bone Joint Surg Am. 1993 Nov;75(11):1585-92. — View Citation
Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;334:1-100. — View Citation
Mokhtari V, Afsharian P, Shahhoseini M, Kalantar SM, Moini A. A Review on Various Uses of N-Acetyl Cysteine. Cell J. 2017 Apr-Jun;19(1):11-17. Epub 2016 Dec 21. Review. — View Citation
Page MJ, Massy-Westropp N, O'Connor D, Pitt V. Splinting for carpal tunnel syndrome. Cochrane Database Syst Rev. 2012 Jul 11;(7):CD010003. doi: 10.1002/14651858.CD010003. Review. — View Citation
Reid AJ, Shawcross SG, Hamilton AE, Wiberg M, Terenghi G. N-acetylcysteine alters apoptotic gene expression in axotomised primary sensory afferent subpopulations. Neurosci Res. 2009 Oct;65(2):148-55. doi: 10.1016/j.neures.2009.06.008. Epub 2009 Jun 24. — View Citation
Sud V, Freeland AE. Biochemistry of carpal tunnel syndrome. Microsurgery. 2005;25(1):44-6. Review. — View Citation
* Note: There are 11 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline Boston Carpal Tunnel Questionnaire (BCTQ) at 8 weeks | The Boston Carpal Tunnel Questionnaire (BCTQ) is a validated tool for patient-reported outcomes with respect to symptoms and functional impact of carpal tunnel syndrome. It consists of both a symptom severity scale (SSS) (11 items) and functional status scale (FSS) (8 items). Each item on both of these scales is scored on a 5-point rating system, with higher numbers indicating more severe symptoms and higher functional disability. The possible range of both the FSS and SSS combined is from 19-95. A baseline BCTQ will be administered at the first visit, which will be used to calculate the overall change in BCTQ score at 8 weeks. | 8 weeks | |
Secondary | Number of participants who elect to have surgical carpal tunnel decompression after 8 weeks | The participant's decision to continue with conservative treatment or to elect to have a carpal tunnel release procedure at 8-weeks post-treatment will be a secondary outcome measure. | 8 weeks | |
Secondary | Number of participants who elect to have surgical carpal tunnel decompression after 6 months | If at 8-weeks, the participant decides not to have carpal tunnel release surgery, an additional follow up visit will be scheduled at 6 months time. At this point in time, the participants decision to have carpal tunnel release surgery or to continue to conservative modalities will be a subgroup analysis. | 6 months | |
Secondary | Change from baseline Boston Carpal Tunnel Questionnaire (BCTQ) at 6 months | If the participant decides not have have a carpal tunnel release at 8 weeks, an additional follow up visit will be scheduled in 6 months. At this time, a third BCTQ will be completed to assess change in long-term BCTQ compared to baseline. | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05067205 -
Minimal Invasive Carpal Tunnel Release With the Novel Device
|
N/A | |
Completed |
NCT03184688 -
Platelet Rich Plasma for Carpal Tunnel Syndrome
|
N/A | |
Completed |
NCT03582735 -
Preoperative Neuromobilization Exercises for Individuals With Carpal Tunnel Syndrome
|
N/A | |
Completed |
NCT05490420 -
Effects of Upper Extremity Manual Lymphatic Drainage on Symptom Severity, Hand Functions, Electrophysiological and Ultrasonographic Measurements in Carpal Tunnel Syndrome
|
N/A | |
Recruiting |
NCT05970692 -
Cross-Cultural Adaptation and Psychometric Validation of the Turkish Version of Atroshi-Lyrén 6-item Symptoms Scale
|
||
Completed |
NCT04043780 -
Clinical Validation of a Decompression Prototype Splint for Patients With Carpal Tunel Syndrome
|
N/A | |
Completed |
NCT03880812 -
Cost Information on Carpal Tunnel Syndrome Treatment Decisions
|
N/A | |
Completed |
NCT06464809 -
Treatment Intervention of Patients With Carpal Tunnel Syndrome (CTS)
|
N/A | |
Recruiting |
NCT05328180 -
aDjunct bicarbonatE in Local anaesthesIa for CarpAl Tunnel rElease (DELICATE)
|
N/A | |
Recruiting |
NCT05503719 -
An Absorbable Suture Versus a Non-absorbable Suture in Carpal Tunnel Release, a Randomized Controlled Trial
|
N/A | |
Recruiting |
NCT05372393 -
Carpal Tunnel Release Under Local Anaesthesia With or Without Distal Median Nerve Block
|
N/A | |
Recruiting |
NCT05466162 -
Soft Tissue Massage Along With Mobilization Technique on Symptoms and Functional Status of Carpal Tunnel Syndrome
|
N/A | |
Completed |
NCT04060875 -
Research Protocol for Karuna Labs Inc.: Safety and Efficacy of Virtual Reality Graded Motor Imagery for Chronic Pain
|
||
Not yet recruiting |
NCT06294821 -
4AP to Delay Carpal Tunnel Release (CTR)
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT04328805 -
Pain Reduction and Changes in Upper Limb Function Produced by an Ibuprofen Treatment in Carpal Tunnel Syndrome.
|
Phase 4 | |
Terminated |
NCT02791529 -
Scalpel Versus Electrocautery for Surgical Skin Incision in Open Carpal Tunnel Release
|
Phase 1 | |
Completed |
NCT02141035 -
Acetyl-l-carnitine to Enhance Nerve Regeneration in Carpal Tunnel Syndrome
|
Phase 2/Phase 3 | |
Completed |
NCT01887145 -
Comparison of Long-term Outcomes Following Endoscopic or Open Surgery for Carpal Tunnel Syndrome
|
N/A | |
Recruiting |
NCT01897272 -
Post-Operative Splinting After Short-Incision Carpal Tunnel Release: a Prospective Study
|
N/A | |
Completed |
NCT01394822 -
Neuromuscular Ultrasound for Focal Neuropathies
|
N/A |